Complications of lipodystrophy syndromes.
Autoimmune Diseases
/ etiology
Diabetes Mellitus
/ etiology
Heart Diseases
/ genetics
Humans
Hypertriglyceridemia
/ etiology
Insulin Resistance
Kidney Diseases
/ complications
Leptin
/ deficiency
Lipid Metabolism
Lipodystrophy
/ complications
Liver
/ metabolism
Metabolic Syndrome
/ etiology
Neuromuscular Diseases
/ etiology
Non-alcoholic Fatty Liver Disease
/ etiology
Pancreatitis
/ etiology
Syndrome
Insulin resistance
Leptin
Lipodystrophy
Organ complications
Journal
Presse medicale (Paris, France : 1983)
ISSN: 2213-0276
Titre abrégé: Presse Med
Pays: France
ID NLM: 8302490
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
04
07
2021
revised:
09
10
2021
accepted:
20
10
2021
pubmed:
4
11
2021
medline:
16
12
2021
entrez:
3
11
2021
Statut:
ppublish
Résumé
Lipodystrophy syndromes are rare complex multisystem disorders caused by generalized or partial lack of adipose tissue. Adipose tissue dysfunction in lipodystrophy is associated with leptin deficiency. Lipodystrophy leads to severe metabolic problems. These abnormalities include, but are not limited to, insulin-resistant diabetes, severe hypertriglyceridemia, and lipid accumulation in ectopic organs such as the liver, and are associated with end-organ complications. Metabolic abnormalities can be present at the time of diagnosis or may develop over time as the disease progresses. In addition to metabolic abnormalities, subtype-specific presentations due to underlying molecular etiology in genetic forms and autoimmunity in acquired forms contribute to severe morbidity in lipodystrophy.
Identifiants
pubmed: 34728268
pii: S0755-4982(21)00024-5
doi: 10.1016/j.lpm.2021.104085
pii:
doi:
Substances chimiques
Leptin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104085Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest BA has attended Scientific Advisory Board Meetings organized by Aegerion Pharmaceuticals (now Amryt Pharma) and Regeneron Pharmaceuticals and has received honoraria as a speaker from AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis. Other authors report no conflicts of interest.